Phathom Pharmaceuticals (PHAT) Competitors $9.04 +0.07 (+0.78%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$9.06 +0.02 (+0.17%) As of 06/11/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. OCUL, BGM, GPCR, AMPH, CALT, AUPH, CVAC, MLYS, PAHC, and RCUSShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Ocular Therapeutix (OCUL), Qilian International Holding Group (BGM), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), CureVac (CVAC), Mineralys Therapeutics (MLYS), Phibro Animal Health (PAHC), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Its Competitors Ocular Therapeutix Qilian International Holding Group Structure Therapeutics Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals CureVac Mineralys Therapeutics Phibro Animal Health Arcus Biosciences Ocular Therapeutix (NASDAQ:OCUL) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Do institutionals & insiders have more ownership in OCUL or PHAT? 59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 2.3% of Ocular Therapeutix shares are owned by insiders. Comparatively, 23.0% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend OCUL or PHAT? Ocular Therapeutix presently has a consensus price target of $16.25, indicating a potential upside of 84.24%. Phathom Pharmaceuticals has a consensus price target of $17.50, indicating a potential upside of 93.58%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Ocular Therapeutix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings and valuation, OCUL or PHAT? Ocular Therapeutix has higher earnings, but lower revenue than Phathom Pharmaceuticals. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$59.65M23.56-$80.74M-$1.15-7.67Phathom Pharmaceuticals$81.86M7.71-$201.59M-$5.24-1.73 Is OCUL or PHAT more profitable? Ocular Therapeutix has a net margin of -283.74% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Ocular Therapeutix's return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% Phathom Pharmaceuticals -1,292.14%N/A -79.57% Does the MarketBeat Community believe in OCUL or PHAT? Ocular Therapeutix received 341 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. However, 73.05% of users gave Phathom Pharmaceuticals an outperform vote while only 70.36% of users gave Ocular Therapeutix an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes44470.36% Underperform Votes18729.64% Phathom PharmaceuticalsOutperform Votes10373.05% Underperform Votes3826.95% Which has more risk and volatility, OCUL or PHAT? Ocular Therapeutix has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Does the media prefer OCUL or PHAT? In the previous week, Phathom Pharmaceuticals had 25 more articles in the media than Ocular Therapeutix. MarketBeat recorded 28 mentions for Phathom Pharmaceuticals and 3 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.36 beat Phathom Pharmaceuticals' score of 0.54 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 4 Very Positive mention(s) 9 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPhathom Pharmaceuticals beats Ocular Therapeutix on 10 of the 19 factors compared between the two stocks. Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$631.12M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-1.598.7827.1720.06Price / Sales7.71255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book-7.126.557.064.70Net Income-$201.59M$143.93M$3.23B$247.88M7 Day Performance92.75%3.97%2.89%2.66%1 Month Performance186.98%11.32%9.06%6.40%1 Year Performance-16.84%4.20%31.40%14.07% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals4.0864 of 5 stars$9.04+0.8%$17.50+93.6%-18.0%$631.12M$81.86M-1.59110Analyst ForecastOptions VolumeHigh Trading VolumeOCULOcular Therapeutix3.8674 of 5 stars$8.11+1.2%$16.25+100.4%+75.7%$1.29B$59.65M-6.14230Positive NewsBGMQilian International Holding GroupN/A$12.90-3.7%N/AN/A$1.25B$25.10M0.00298Positive NewsGap UpGPCRStructure Therapeutics2.291 of 5 stars$21.79+0.1%$79.86+266.5%-54.6%$1.25BN/A-29.45136News CoveragePositive NewsAnalyst RevisionAMPHAmphastar Pharmaceuticals3.6564 of 5 stars$25.38-1.3%$32.33+27.4%-36.7%$1.20B$730.66M8.461,620CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.3319 of 5 stars$7.96+1.5%$11.50+44.5%+45.8%$1.08B$247.30M-53.06300Positive NewsAnalyst RevisionCVACCureVac4.3007 of 5 stars$4.63+3.6%$11.00+137.6%-4.2%$1.04B$523.70M8.42880Positive NewsMLYSMineralys Therapeutics3.3374 of 5 stars$15.70+0.8%$38.00+142.0%+19.7%$1.02BN/A-4.3128Analyst ForecastPAHCPhibro Animal Health3.8772 of 5 stars$24.58+0.7%$20.00-18.6%+45.6%$996.33M$1.19B51.211,860Positive NewsRCUSArcus Biosciences2.5159 of 5 stars$9.21+3.1%$25.67+178.8%-41.9%$974.67M$141M-2.92500News CoverageOptions VolumeAnalyst RevisionGap Up Related Companies and Tools Related Companies Ocular Therapeutix Alternatives Qilian International Holding Group Alternatives Structure Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives Aurinia Pharmaceuticals Alternatives CureVac Alternatives Mineralys Therapeutics Alternatives Phibro Animal Health Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAT Stock Free PHAT Stock Alerts